M Capezzone1, E Robenshtok2,3, S Cantara1, M G Castagna4. 1. Section of Endocrinology and Metabolism, Department of Medical, Surgical and Neurological Sciences, University of Siena, Policlinico Santa Maria alle Scotte, Viale Bracci 1, 53100, Siena, Italy. 2. Institute of Endocrinology, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel. 3. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 4. Section of Endocrinology and Metabolism, Department of Medical, Surgical and Neurological Sciences, University of Siena, Policlinico Santa Maria alle Scotte, Viale Bracci 1, 53100, Siena, Italy. mariagrazia.castagna@unisi.it.
Abstract
BACKGROUND: Familial non-medullary thyroid carcinoma (FNMTC), mainly of papillary histotype (FPTC), is defined by the presence of the disease in two or more first-degree relatives in the absence of other known familial syndromes. With the increasing incidence of PTC in the recent years, the familial form of the disease has also become more common than previously reported and constitutes nearly 10% of all thyroid cancers. Many aspects of FNMTC are debated, concerning both clinical and genetic aspects. Several studies reported that, in comparison with sporadic PTCs, FPTCs are more aggressive at disease presentation, while other authors reported no differences in the clinical behavior of sporadic and familial PTCs. For this reason, recent guidelines do not recommend screening of family members of patients with diagnosis of differentiated thyroid cancer (DTC). FNMTC is described as a polygenic disorder associated with multiple low- to moderate-penetrance susceptibility genes and incomplete penetrance. At the moment, the genetic factors contributing to the development of FNMTC remain poorly understood, though many putative genes have been proposed in the recent years. PURPOSE: Based on current literature and our experience with FNMTC, in this review, we critically discussed the most relevant controversies, including its definition, the genetic background and some clinical aspects as screening and treatment.
BACKGROUND: Familial non-medullary thyroid carcinoma (FNMTC), mainly of papillary histotype (FPTC), is defined by the presence of the disease in two or more first-degree relatives in the absence of other known familial syndromes. With the increasing incidence of PTC in the recent years, the familial form of the disease has also become more common than previously reported and constitutes nearly 10% of all thyroid cancers. Many aspects of FNMTC are debated, concerning both clinical and genetic aspects. Several studies reported that, in comparison with sporadic PTCs, FPTCs are more aggressive at disease presentation, while other authors reported no differences in the clinical behavior of sporadic and familial PTCs. For this reason, recent guidelines do not recommend screening of family members of patients with diagnosis of differentiated thyroid cancer (DTC). FNMTC is described as a polygenic disorder associated with multiple low- to moderate-penetrance susceptibility genes and incomplete penetrance. At the moment, the genetic factors contributing to the development of FNMTC remain poorly understood, though many putative genes have been proposed in the recent years. PURPOSE: Based on current literature and our experience with FNMTC, in this review, we critically discussed the most relevant controversies, including its definition, the genetic background and some clinical aspects as screening and treatment.
Entities:
Keywords:
Familial non medullary thyroid cancer; Familial papillary thyroid cancer; Syndromic thyroid cancer
Authors: Sara Gandini; Francesco Sera; Maria Sofia Cattaruzza; Paolo Pasquini; Roberto Zanetti; Cinzia Masini; Peter Boyle; Carmelo Francesco Melchi Journal: Eur J Cancer Date: 2005-09 Impact factor: 9.162
Authors: Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt Journal: Am J Gastroenterol Date: 2015-02-03 Impact factor: 10.864
Authors: Irma Kluijt; Rolf H Sijmons; Nicoline Hoogerbrugge; John T Plukker; Daphne de Jong; J Han van Krieken; Richard van Hillegersberg; Marjolijn Ligtenberg; Eveline Bleiker; Anemieke Cats Journal: Fam Cancer Date: 2012-09 Impact factor: 2.375
Authors: Phuong L Mai; Anne O Garceau; Barry I Graubard; Marsha Dunn; Timothy S McNeel; Lou Gonsalves; Mitchell H Gail; Mark H Greene; Gordon B Willis; Louise Wideroff Journal: J Natl Cancer Inst Date: 2011-05-11 Impact factor: 13.506
Authors: Jinyoung Byun; Ann G Schwartz; Christine Lusk; Angela S Wenzlaff; Mariza de Andrade; Diptasri Mandal; Colette Gaba; Ping Yang; Ming You; Elena Y Kupert; Marshall W Anderson; Younghun Han; Yafang Li; David Qian; Adrienne Stilp; Cathy Laurie; Sarah Nelson; Wenying Zheng; Rayjean J Hung; Valerie Gaborieau; James Mckay; Paul Brennan; Neil E Caporaso; Maria Teresa Landi; Xifeng Wu; John R McLaughlin; Yonathan Brhane; Yohan Bossé; Susan M Pinney; Joan E Bailey-Wilson; Christopher I Amos Journal: Carcinogenesis Date: 2018-09-21 Impact factor: 4.944
Authors: G Arpino; M Pensabene; C Condello; R Ruocco; I Cerillo; R Lauria; V Forestieri; M Giuliano; C De Angelis; M Montella; A Crispo; S De Placido Journal: BMC Cancer Date: 2016-11-29 Impact factor: 4.430
Authors: M Capezzone; F Maino; A Sagnella; M Campanile; C Dalmiglio; T Pilli; R Forleo; M G Castagna Journal: J Endocrinol Invest Date: 2021-02-12 Impact factor: 4.256
Authors: Luis Eduardo Barbalho de Mello; Thaise Nayane Ribeiro Carneiro; Aline Neves Araujo; Camila Xavier Alves; Pedro Alexandre Favoretto Galante; Vanessa Candiotti Buzatto; Maria das Graças de Almeida; Karina Marques Vermeulen-Serpa; Sancha Helena de Lima Vale; Fernando José de Pinto Paiva; José Brandão-Neto; Janete Maria Cerutti Journal: Endocr Connect Date: 2022-01-31 Impact factor: 3.335